SAVANNAH, Ga. -- Investigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III ...

and nipocalimab for myasthenia gravis. Merck & Co.’s clesrovimab is an investigational prophylactic long-acting monoclonal antibody (mAb) targeted at the RSV fusion glycoprotein that is designed ...

For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).

In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address unmet needs for patients with generalized myasthenia gravis.

Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.

that are integral to the pathogenesis of generalized myasthenia gravis," noted Richard Nowak, MD, MS, of Yale University in New Haven, Connecticut. In the Vivacity-MG3 trial, nipocalimab lessened ...

The promising results underscore nipocalimab's potential to address IgG-driven diseases such as generalized myasthenia gravis or gMG and other autoimmune disorders. The drug has already received ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Myasthenia gravis (MG) should be classified according to antibody status (acetylcholine, MuSK, LRP4, titin), thymus (hyperplasia, neoplasia, atrophy), age at debut (< or >50 years), symptom ...

J&J is running a broad programme of clinical trials for nipocalimab, with phase 3 studies already on the go in generalised myasthenia gravis (gMG), chronic inflammatory demyelinating ...